Skip to main content
VTRS
NASDAQ Life Sciences

Pacira Faces Two Merger Suits and 15 Demand Letters Over 14D-9 Disclosures

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$20.69
Mkt Cap
$23.697B
52W Low
$10.15
52W High
$21.2
52W Position info
104% above low
Off High info
2.4% below high
Rel. Volume info
1.0× avg
Market data snapshot near publication time

VTRS has more than doubled off its 52-week low of $10.15.

Summary

Two New York state stockholder suits and fifteen demand letters claim Pacira's 14D-9 omitted material information about the $36.50-a-share Viatris buyout; plaintiffs want the deal enjoined until more is disclosed.


Key Events · M&A and Partnerships · VTRS

  • Two Merger Suits Filed

    In New York Supreme Court, Carroll v. Pacira (Index No. 656215/2026) and Burke v. Pacira (Index No. 656243/2026) name Pacira and each board member, alleging the Schedule 14D-9 omitted or misrepresented material merger information.

  • Relief Sought Includes Injunction

    The plaintiffs seek preliminary and permanent injunctive relief blocking the transaction until disclosure is corrected, or rescission and actual plus punitive damages if it closes, plus fees and expenses.

  • Fifteen Demand Letters Received

    Pacira has received fifteen demand letters, including two draft complaints, generally seeking disclosure of information allegedly omitted from the Schedule 14D-9.

  • Tender Offer Runs to November 16

    Launched October 30, 2026, the $36.50-a-share all-cash offer for all Pacira shares is scheduled to expire November 16, 2026; the suits target that timeline.


Analysis · VTRS · Life Sciences

The adequacy of Pacira's Schedule 14D-9 disclosure for the $36.50-a-share Viatris tender offer is now under attack from two stockholder suits and fifteen demand letters. Plaintiffs want the deal blocked until more information is disclosed, or rescission and damages if it closes. Such disclosure-only merger litigation is common and typically settles for supplemental disclosure, but an injunction delaying the November 16 expiration would put the $1.65 billion deal's timing at risk. Pacira says it will defend the disclosures and has not yet been served.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, VTRS was trading at $20.69 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $23.7B. The 52-week trading range was $10.15 to $21.20. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

VTRS - Latest Insights

VTRS
Nov 05, 2026, 9:23 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $19.40
Real-time Price: $20.94 info
Change: +$1.54 (+8%) info
Market Cap: $23.697B info
VTRS
Nov 05, 2026, 7:45 AM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $19.33
Real-time Price: $20.94 info
Change: +$1.61 (+8%) info
Market Cap: $23.697B info
VTRS
Nov 05, 2026, 6:59 AM EST
Source: Dow Jones Newswires
Importance Score:
7
Price at Filing: $19.36
Real-time Price: $20.94 info
Change: +$1.58 (+8%) info
Market Cap: $23.697B info
VTRS
Oct 30, 2026, 7:40 AM EDT
Filing Type: SC TO-T
Importance Score:
8
Price at Filing: $19.30
Real-time Price: $20.94 info
Change: +$1.64 (+8%) info
Market Cap: $23.697B info
VTRS
Oct 16, 2026, 4:05 PM EDT
Source: PR Newswire
Importance Score:
7
Price at Filing: $18.20
Real-time Price: $20.94 info
Change: +$2.74 (+15%) info
Market Cap: $23.697B info